Table 3.
Patient demographics and disease burden over 24 months follow-up by adherence to initial LABD therapy
| LAMA | LABA | LABA+ICS | ||||
|---|---|---|---|---|---|---|
| MPR > = 80 % | MPR < 80 % | MPR > = 80 % | MPR < 80 % | MPR > = 80 % | MPR < 80 % | |
| (N = 2460) | (N = 3341) | (N = 355) | (N = 678) | (N = 2630) | (N = 5102) | |
| Gender, male (%) | 58 | 56 | 50 | 53 | 52 | 53 |
| Age at index date, Mean (SD) | 70.1 (10.0) | 68.5 (10.5) | 70.0 (10.2) | 67.4 (10.6) | 69.6 (10.7) | 67.6 (11.6) |
| Comorbidities, Mean CCI (SD)a | 0.3 (0.7) | 0.3 (0.7) | 0.3 (0.7) | 0.2 (0.6) | 0.2 (0.6) | 0.2 (0.7) |
| Baseline BMI kg/m2, Mean (SD) | 27.0 (6.2) | 27.5 (6.2) | 27.4 (6.0) | 27.9 (6.0) | 27.2 (6.4) | 27.8 (6.4) |
| Dyspnea (%)b | ||||||
| MRC < 3 | 59 | 60 | 55 | 62 | 56 | 60 |
| MRC ≥ 3 | 41 | 40 | 45 | 38 | 44 | 40 |
| Any exacerbations (Moderate to severe)c | ||||||
| Rate per PY (95 % CI) | 0.44 (0.41-0.47) | 0.40 (0.38-0.42) | 0.48 (0.41-0.57) | 0.43 (0.39-0.48) | 0.71 (0.68-0.74) | 0.57 (0.55-0.59) |
| Mean Time to first event, months (SD) | 6.7 (5.9) | 7.8 (5.9) | 6.7 (6.5) | 7.7 (5.9) | 6.5 (5.8) | 7.6 (5.9) |
| Hospitalized (Severe) COPD exacerbations | ||||||
| Rate per PY (95 % CI) | 0.22 (0.21-0.24) | 0.13 (0.12-0.14) | 0.19 (0.14-0.24) | 0.10 (0.08-0.12) | 0.23 (0.22-0.25) | 0.15 (0.14-0.16) |
| Mean Time to first event, months (SD) | 8.2 (6.6) | 9.9 (6.8) | 6.7 (6.4) | 9.2 (6.2) | 8.5 (6.8) | 9.4 (6.6) |
| Non-COPD hospitalizations | ||||||
| Rate per PY (95 % CI) | 0.34 (0.32-0.36) | 0.39 (0.37-0.41) | 0.31 (0.25-0.38) | 0.37 (0.33-0.42) | 0.38 (0.36-0.41) | 0.47 (0.45-0.48) |
CI, confidence interval; CCI, Charlson Comorbidity Index; COPD, chronic obstructive pulmonary disease; ICS, inhaled corticosteroid; LABA, long-acting beta2-agonist; LABD, long-acting bronchodilator; LAMA, long-acting muscarinic antagonist; MRC, Medical Research Council dyspnea scale 1-5; FEV1, Forced expiratory volume; PY, person years; SD, standard deviation
aCharlson Comorbidity Index score calculated based on co-morbidities recorded any time in the patient history up until the index date
bPercentages represent distribution in patients with a known value. Dyspnea data unknown for N = 1159 (47 %) LAMA users with MPR > = 80 % and N = 1093 (33 %) with MPR <80 %; N = 198 (56 %) of LABA users with MPR > = 80 % and N = 281 (41 %) with MPR <80 %; N = 1160 (44 %) LABA+ICS users with MPR > = 80 % and N = 1646 (32 %) with MPR <80 %
cHealth care resource use and exacerbation data during the time period of index medication to the final prescription used in the MPR calculation (over 24 months of follow- up)